Research programme: botulinum toxin A - Allergan

Drug Profile

Research programme: botulinum toxin A - Allergan

Alternative Names: AI-09

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Anterios
  • Developer Allergan
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acne; Facial-wrinkles; Hyperhidrosis

Most Recent Events

  • 07 Jan 2016 Anterios has been acquired by Allergan
  • 19 Mar 2014 Preclinical trials in Acne in USA (Injection)
  • 19 Mar 2014 Preclinical trials in Facial wrinkles in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top